Stewart takes responsibility for maximising the value of Amarin’s lead product, AMR101, a new drug currently in Phase 3 clinical trials for the treatment of high triglycerides. The company has also completed enrolment to its Phase 3 Marine trial earlier than expected, with results now due early next year.
Stewart has more than 30 years of experience in the pharmaceutical industry, including five as ceo of CollaGenex Pharmaceuticals. He also worked for the ASTA Medica Group, where for 10 years he managed several business units in the US and internationally. He began his career in sales and marketing for Winthrop Laboratories, in the UK, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.
Declan Doogan, who has been the company’s interim ceo, will continue to support Amarin as chief medical officer for the majority of his time.
Amarin names Colin Stewart as president and ceo
Has been in the pharmaceutical industry for more than 30 years
You may also like
Manufacturing
Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development